Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19

Abstract

This cohort study investigates whether early aspirin use is associated with lower 28-day in-hospital mortality among patients with moderate COVID-19.

Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper

“…A systematic review including 12 studies suggested that aspirin may improve mortality in hospitalized patients with severe COVID-19 [ 237 ]. An observational cohort study of 112,269 hospitalized patients with COVID-19 also showed that early aspirin use was associated with lower odds of inpatient death [ 238 ]. However, the multiplatform RECOVERY trial found that aspirin was not associated with reductions in 28-day mortality or rates of invasive mechanical ventilation [ 239 ].…”

A closer look at endothelial injury-induced platelet hyperactivity and the use of aspirin in the treatment of COVID infection

“…We found Chow et al’s recent findings published in JAMA on aspirin’s effect on early-stage patients with moderate COVID disease (Chow et al 2022 ) both compelling and potentially of important clinical significance. In summary, they performed a retrospective analysis from 64 health systems in the US, that placing 112,269 hospitalized COVID patients with moderate symptoms on low-dose 81 mg aspirin over the first 5 days of hospitalization significantly lowered both the development of pulmonary edema and mortality with the benefits enhanced in patients with multiple co-morbidities.…”

Ischemic Stroke and SARS-CoV-2 Infection: The Bidirectional Pathology and Risk Morbidities

“…Berger et al [ 118 ] evaluated the benefits and risks of adding a P2Y12 inhibitor to anticoagulant therapy among non-critically ill patients hospitalized for COVID-19, reporting no increased odds of improvement in organ-support-free days within 21 days during hospitalization. Similarly, Chow et al [ 119 ] in their study of adults hospitalized with moderate COVID-19 showed that early aspirin use was associated with lower odds of 28-day in-hospital mortality. Further randomized clinical trials that include diverse patients with different COVID-19 clinical condition are warranted to adequately evaluate heparin and aspirin’s efficacy in patients with different risk conditions.…”